Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65329 | 0.91 | HRH3 (0.47) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL2553841 | 0.87 | HRH3 (0.44) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL2550326 | 0.85 | L3MBTL3 (0.46) | HRH3KCNH2KDM4EALDH1A1L3MBTL3 | |
| SCHEMBL4720502 | 0.83 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1 | |
| SCHEMBL3768409 | 0.83 | POLB (0.56) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL65252 | 0.83 | POLB (0.52) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL861595 | 0.82 | HRH3 (0.41) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL3601428 | 0.81 | POLB (0.59) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL18619500 | 0.81 | POLB (0.59) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL3832331 | 0.81 | HRH3 (0.36) | HRH3KCNH2POLBHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | claimed |
| CN-101365698-A | 2-urea-4-phenylthiazole derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-02-11 | — | — | CN | claimed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | claimed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2023072270-A1 | PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 百极弘烨(南通)医药科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| CN-101365698-A | 2-urea-4-phenylthiazole derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-02-11 | — | — | CN | disclosed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PKD2, QPCT, CCNT2 | HRH3 601/4885KCNH2 870/4885POLB 4267/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885KCNH2 4751/4885POLB 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.